HOMOLOGY MEDICINES INC stock forecast: up to 1.60 USD FIXX stock price prognosis
Forecast for Fri 20 Jan 2023 price
HOMOLOGY MEDICINES INC stock price forecast for further price development up to 3.12% (time horizon: 1 day) and price target of 1.60 USD. Negative news sentiment. Short-term (time horizon: 2 weeks) HOMOLOGY MEDICINES INC share price prediction for 2023-01-20 with daily closed price projections
News <--> Close correlation for next day influence (-0.06)
Earnings per share
On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.
The forecast (dashed curve) of the share price performance is based on historical data.
Our forecast model is based on mathematical, statistical methods.
The website offers price forecasts and analysis tools for equities and other securities,
which are exclusively based on the prices of these securities in the past.
Information about these prices is provided to us by third parties. Although we believe,
If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and
correct sequencing of this information.
We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider
any financial data or other data of such issuers with the exception of the past prices of the securities.
Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or
that may be relevant for future security price flows. Investments require additional considerations.
Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor
or the tax implications an investment may have for the investor. Although we believe that
our mathematical models are a tool to try to explore the possibility for future price development
with the help of past performance, such developments are subject to a multitude of different influences.
and therefore not really predictable.
We cannot guarantee the success of any investment you make based on the information published here.
This website is for information purposes only. All information and data on this website cannot be guaranteed
to be accurate,
accuracy, completeness and appropriateness - neither explicit nor implicit.
Summerized Form 10-K with GPT-2
HMI-203 also led to significant changes in skeletal deformities compared with vehicle. We expect to initiate a Phase 1/2 dose-escalation clinical trial with HMI-103 in 2021. 8226; Control manufacturing through our in-house capabilities. In vivo gene editing proof-of-concept at the murine F8 locus. These findings were published in Human Gene Therapy Clinical Development in March 2018. PKU results from mutations in PAH that render its enzymatic activity deficient. Worldwide sales of Kuvan were $458 million in 2020. These data were presented at WORLDSymposium™ in February 2021. We may terminate the agreement for convenience. These so-called Phase 4 studies may also be made a condition to approval of the BLA. PDUFA also imposes an annual program fee for marketed products. Additionally, a product may be eligible for accelerated approval. The FDA does not regulate the behavior of physicians in their choice of treatments. Other national and European Union-wide regulatory requirements may also apply. As of December 31, 2020, we had an accumulated deficit of approximately $328.4 million. We were established and began operations in 2015. We may not be successful in such a transition. Moreover, none of those trials has involved our nuclease-free gene editing technology. The same principles are valid for the EU as well. Further, the CPRA was also recently voted into law by California residents. As a result, increasingly high barriers are being erected to the entry of new products. We also do not have long-term supply agreements with any of our component suppliers. It is not clear what, if any, impact the AIA will have on the operation of our business. We currently in-license certain intellectual property from COH and Caltech. The COVID-19 pandemic continues to rapidly evolve. Item 1B. Unresolved Staff Comments.
Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.
Meta analyst score 39.06/100
Good financial position.
Historical view, profit is growing.
Company revenue is not growing faster compared with the
Institutional ownership list is based on filling form information
Bollinger Bollinger Bands for HOMOLOGY MEDICINES INC can provide the information where the market is moving based on price information.
HOMOLOGY MEDICINES INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.
On-Balance Volume information for HOMOLOGY MEDICINES INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.
Accumulation / Distribution (A/D) indicator information for HOMOLOGY MEDICINES INC. The indicator identify divergences between price and volume flow.
Aroon Oscillator information for HOMOLOGY MEDICINES INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.
Average Directional Index (ADX) information for HOMOLOGY MEDICINES INC. The index can be used to identify the strengh of a trend.
Moving Average Convergence Divergence (MACD) for HOMOLOGY MEDICINES INC. The indicator helps to predict trend direction and the momentum of the trend.
Stochastic Oscillator as momentum indicator for HOMOLOGY MEDICINES INC. The indicator is useful for identifying overbought and oversold levels.
Relative Strength Index (RSI) for HOMOLOGY MEDICINES INC. RSI is a momentum oscillator that measures the speed and change of price development.
The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period.
Primary usage of the indicator is to identify overbought or oversold signals.
When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30
Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio